NewsCall For Nominations: TÜBA 2018 Academy Prizes Applications for the 2018 TÜBA-GEBİP and TÜBA-TESEP Awards Have Started The 52nd TÜBA General Assembly was Held 2017 “TÜBA Awards” Found Their Owners TÜBA 2017 Academy Prizes Awarded Winners of TÜBA GEBIP and TÜBA TESEP Awards Announced TÜBA President Prof. Acar and Council Member Prof. Şeker Attended 8th World Science Forum TÜBA Council Member Prof. Şahin Represented TÜBA at “IASSF2017” TÜBA&EMAN Symposium on “Exploring the Commonalities of the Mediterranean Region” “TÜBA-Food Safety Symposium: Organic Products and Health” was Held at İnönü University
Significant Success of The Principal Member of TÜBA, Prof. Dr. Gökhan Hotamışlıgil and his team
Tarih: 09 OCAK 2014 Okunma Sayısı: 28008
New researches, led by Gökhan Hotamışlıgil who is the Principal Member of TÜBA in Harvard University Genetics and Complex Diseases Departmant,has revealed a mechanism which plays an important role in destruction of beta cells responsible for producing type 1 insulin in diabetes. Furthermore, researches show that this disease could be avoided by a medicine which is natural and effective enough to stop the destruction, on the other hand, using naturally occuring bile acid introduces a new and effective protection and treatment against type 1 diaebetes.
Prof. Dr. Hotamışlıgil stressed the importance of hard work and said: “The results of this study shows us that diabetes could be avoided just by protecting beta cells even without concerning the immune system, thus a new era opens for treatment of the disease. Our finding mechanism and chemical have the capacity for delaying the occurence of the illness considerably or even destroying it completely for children who are in this phase. Thanks to those found mechanisms, we anticipate that other chemicals will be improved for the same object and alternatives will be reached which people-at-risk need strongly.
On November 13th, 2013, one of the leading science magazines Science TM reported Dr. Gökhan Hotamışlıgil and his team’s study which is supported by Juvenile Diabetes Research Foundation (JDRF).